Skye Bioscience Engages Clinical Trial Site for Phase 1 Study in Agreement with CMAX Clinical Research
April 28, 2022
Ryan Allway April 28th, 2022 News, Top News San Diego, California, April 28, 2021 — Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing proprietary, synthetic cannabinoid derivatives to treat glaucoma and other diseases with significant unmet need, has retained CMAX Clinical Research (“CMAX”) to facilitate enrollment of and... Read more
Skye Bioscience Issues Shareholder Letter Providing Progress Update and Business Outlook for 2022
January 10, 2022
Ryan Allway January 10th, 2022 SAN DIEGO, CA, Jan 10, 2022 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a pharmaceutical company developing proprietary, synthetic, cannabinoid-derived molecules to treat diseases with significant unmet need, issued today the following letter from Chief Executive Officer and Chair, Punit Dhillon. Dear... Read more
